Compare MTZ & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTZ | EXAS |
|---|---|---|
| Founded | 1929 | 1995 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 19.6B |
| IPO Year | 2005 | 2000 |
| Metric | MTZ | EXAS |
|---|---|---|
| Price | $275.54 | $103.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 19 |
| Target Price | ★ $238.42 | $84.27 |
| AVG Volume (30 Days) | 726.0K | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 421.88 | 80.32 |
| EPS | ★ 3.26 | N/A |
| Revenue | ★ $12,303,464,000.00 | $4,144,000.00 |
| Revenue This Year | $15.50 | $15.18 |
| Revenue Next Year | $10.18 | $12.46 |
| P/E Ratio | $81.15 | ★ N/A |
| Revenue Growth | ★ 2.56 | N/A |
| 52 Week Low | $99.70 | $38.88 |
| 52 Week High | $276.79 | $103.87 |
| Indicator | MTZ | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 69.75 | 67.66 |
| Support Level | $259.93 | $103.14 |
| Resistance Level | $276.79 | $103.42 |
| Average True Range (ATR) | 11.95 | 0.34 |
| MACD | 1.23 | -0.13 |
| Stochastic Oscillator | 94.10 | 67.53 |
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.